Company: AZN
Filing Date: 2025-07-29
Form Type: 6-K
Source: 0001104659-25-071432
Chunk: 25

Company: ASTRAZENECA PLC
Filing Date: 2025-07-29
Form: 6-K
Chunk 25
---
 of revenue types with similar characteristics, reflecting the growing importance of Alliance Revenue. Full descriptions of Product Sales, Alliance Revenue and Collaboration Revenue are included from page 152 of the Group’s Annual Report and Form 20-F Information 2024. There are no changes to the Revenue accounting policy regarding the types of transactions recorded in each revenue category. The comparative period has been retrospectively adjusted to reflect the additional subtotal, resulting in total Product Revenue being reported for the half year ended 30 June 2024 of $ 25,568 m. Going concern The Group has considerable financial resources available. As at 30 June 2025, the Group has $ 11.9bn in financial resources (cash and cash equivalent balances of $ 7.1bn and undrawn committed bank facilities of $ 4.9bn that are available until April 2030), with $ 6.9bn of borrowings due within one year. These facilities contain no financial covenants. The Group has assessed the prospects of the Group over a period longer than the required 12 months from the date of Board approval of these consolidated financial statements, with no deterioration noted requiring a further extension of this review. The Group's revenues are largely derived from sales of medicines covered by patents, which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to adversely affect revenues in some of our significant markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas.

37

Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully. Accordingly, they continue to adopt the going concern basis in preparing the Interim financial statements. Legal proceedings The information contained in Note 5 updates the disclosures concerning legal proceedings and contingent liabilities in the Group’s Annual Report and Form 20-F Information 202 4. Note 2: Intangible assets The acquisition of EsoBiotec completed on 19 May 2025. The transaction is recorded as an asset acquisition based upon the concentration test permitted under IFRS 3 ‘Business Combinations’, with consideration and net assets acquired of $ 403 m, which included intangible assets acquired of $ 426 m, current payables of $ 29 m, $ 4 m of cash and cash equivalents and current receivables of $ 2 m.